MULTI BARRIER REVERSE CONVERTIBLE - NOVARTIS N/BAYER/ROCHE GS Share Price

Certificat

GRNEFG

CH1145442963

Market Closed - Swiss Exchange 16:20:00 17/05/2024 BST
64.86 CHF +0.46% Intraday chart for MULTI BARRIER REVERSE CONVERTIBLE - NOVARTIS N/BAYER/ROCHE GS
3 months+4.55%
6 months-23.22%
Date Price Change
17/05/24 64.86 +0.46%
16/05/24 64.56 +0.03%
15/05/24 64.54 +0.08%
13/05/24 64.49 +1.10%

Delayed Quote Swiss Exchange

Last update May 17, 2024 at 04:20 pm

More quotes

Static data

Product typeReverse Convertibles
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer LEONTEQ
GRNEFG
ISINCH1145442963
Date issued 24/11/2021
Strike 361.2 CHF
Maturity 25/11/2024 (188 Days)
Parity 0.36 : 1
Emission price 100 CHF
Emission volume N/A
Settlement both
Currency CHF

Technical Indicators

Highest since issue 102.1 CHF
Lowest since issue 62.04 CHF

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
234.4 CHF
Average target price
279.4 CHF
Spread / Average Target
+19.19%
Consensus
  1. Stock Market
  2. Certificates
  3. GRNEFG Certificat